STAT

Kale crackers and hibiscus tea: My five days on a ‘fasting diet’

I tried the five-day ProLon diet, an ultra-low-calorie regimen meant to trick your body into thinking you're fasting. It wasn't as bad as I'd feared.

LOS ANGELES — The box is lovely, sleek and white. But it’s so small.

I’ve decided to try the ProLon diet — five days of “mimicking fasting” that is supposed to help me lose weight, trim belly fat, drop my cholesterol and glucose levels into healthier zones, and even slow aging. I’ve been researching the science behind fasting — check out my full story on that topic here — so I’m excited to try it myself.

But the box is so small. Not much larger than a shoebox, it contains all the food and drink, other than water, that I’ll get for five days. I sift through the futuristic-looking — and tiny — packets of olives and freeze-dried soups, kale chips, and nut bars. I love food so much. I’m a little bit worried.

The diet consists of an ultra-low-calorie blend of proteins, carbohydrates, fats, and nutrients that’s meant to trick the body into thinking it is fasting, but with less discomfort or risk than a true water-only fast. That’s according to its inventor, biochemist Valter Longo, the director of the Longevity Institute at the University of Southern California.

He’s launched a company, L-Nutra, to market the diet; it’s sold for $300 per

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Sanofi Licensing Novavax’s Covid Shot, Moderna’s RSV Vaccine, And More
Sanofi said it has reached a licensing deal to sell Novavax’s Covid shot as well as to try to combine the vaccine with Sanofi’s own flu vaccine.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About FDA Dithering On Pharma Patents, WHO Pandemic Talks, And More
When it comes to a crucial controversy over patents for drug-and-device combination products, the FDA has been MIA.
STAT2 min readAmerican Government
STAT+: Pharmalittle: We’re Reading About FTC Reviewing Novo-Catalent Deal, Amneal Opioid Settlement, And More
The FTC wants more information on a $16.5 million deal in which Novo Nordisk's parent company would purchase Catalent, a contract drug manufacturer.

Related Books & Audiobooks